164 related articles for article (PubMed ID: 38577093)
1. Comparison of prognosis and postoperative morbidities between standard pancreaticoduodenectomy and the TRIANGLE technique for resectable pancreatic ductal adenocarcinoma.
Hang HX; Cai ZH; Yang YF; Fu X; Qiu YD; Cheng H
World J Gastrointest Surg; 2024 Mar; 16(3):689-699. PubMed ID: 38577093
[TBL] [Abstract][Full Text] [Related]
2. TRIANGLE operation, combined with adequate adjuvant chemotherapy, can improve the prognosis of pancreatic head cancer: A retrospective study.
Chen JH; Zhu LY; Cai ZW; Hu X; Ahmed AA; Ge JQ; Tang XY; Li CJ; Pu YL; Jiang CY
World J Gastrointest Oncol; 2024 May; 16(5):1773-1786. PubMed ID: 38764839
[TBL] [Abstract][Full Text] [Related]
3. [Analysis on the clinical therapeutic effects of arterial first approach pancreatoduodenectomy in the treatment of borderline resectable pancreatic adenocarcinoma].
Jin G; Zheng KL; Guo SW; Shao Z; Liu C; Shi XH; Liu RD; Bai SJ; Jiang H; Bian Y; Hu XG
Zhonghua Wai Ke Za Zhi; 2017 Dec; 55(12):909-915. PubMed ID: 29224265
[No Abstract] [Full Text] [Related]
4. The TRIANGLE operation for pancreatic head and body cancers: early postoperative outcomes.
Klotz R; Hackert T; Heger P; Probst P; Hinz U; Loos M; Berchtold C; Mehrabi A; Schneider M; Müller-Stich BP; Strobel O; Diener MK; Mihaljevic AL; Büchler MW
HPB (Oxford); 2022 Mar; 24(3):332-341. PubMed ID: 34294523
[TBL] [Abstract][Full Text] [Related]
5. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
6. Mesenteric approach during pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.
Hirono S; Kawai M; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Ueno M; Shimokawa T; Nakao A; Yamaue H
Ann Gastroenterol Surg; 2017 Sep; 1(3):208-218. PubMed ID: 29863125
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of distal pancreatectomy with celiac axis resection and sub-adventitial divestment technique for locally advanced or borderline resectable pancreatic body cancer].
Huang XM; Yin J; Lu ZP; Chen JM; Cai BB; Wu PF; Jiang KR; Miao Y
Zhonghua Wai Ke Za Zhi; 2022 May; 60(5):441-448. PubMed ID: 35359085
[No Abstract] [Full Text] [Related]
8. Laparoscopic versus open pancreatic resection for ductal adenocarcinoma: separate propensity score matching analyses of distal pancreatectomy and pancreaticoduodenectomy.
Chen K; Pan Y; Huang CJ; Chen QL; Zhang RC; Zhang MZ; Wang GY; Wang XF; Mou YP; Yan JF
BMC Cancer; 2021 Apr; 21(1):382. PubMed ID: 33836678
[TBL] [Abstract][Full Text] [Related]
9. High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study.
Lee DH; Ha HI; Jang JY; Lee JW; Choi JY; Bang S; Lee CH; Kim WB; Lee SS; Kim SC; Kang BK; Lee JM
Eur Radiol; 2023 Sep; 33(9):5965-5975. PubMed ID: 36988715
[TBL] [Abstract][Full Text] [Related]
10. MAPLE-PD trial (Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer during Pancreaticoduodenectomy): study protocol for a multicenter randomized controlled trial of 354 patients with pancreatic ductal adenocarcinoma.
Hirono S; Kawai M; Okada KI; Fujii T; Sho M; Satoi S; Amano R; Eguchi H; Mataki Y; Nakamura M; Matsumoto I; Baba H; Tani M; Kawabata Y; Nagakawa Y; Yamada S; Murakami Y; Shimokawa T; Yamaue H
Trials; 2018 Nov; 19(1):613. PubMed ID: 30409152
[TBL] [Abstract][Full Text] [Related]
11. The prognostic influence of intrapancreatic tumor location on survival after resection of pancreatic ductal adenocarcinoma.
Ruess DA; Makowiec F; Chikhladze S; Sick O; Riediger H; Hopt UT; Wittel UA
BMC Surg; 2015 Nov; 15():123. PubMed ID: 26615588
[TBL] [Abstract][Full Text] [Related]
12. Vascular resection for locally advanced pancreatic ductal adenocarcinoma: analysis of long-term outcomes from a single-centre series.
Feo CF; Deiana G; Ninniri C; Cherchi G; Crivelli P; Fancellu A; Ginesu GC; Porcu A
World J Surg Oncol; 2021 Apr; 19(1):126. PubMed ID: 33866970
[TBL] [Abstract][Full Text] [Related]
13. Pancreatico-Duodenectomy for Pancreatic Ductal Adenocarcinoma: from Artery-First Approaches toTRIANGLE Operation.
Dumitraşcu T; Popescu I
Chirurgia (Bucur); 2022 Jun; 117(4):377-384. PubMed ID: 36049094
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of laparoscopic versus open pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic cancer: a retrospective cohort study.
Li Z; Zhuo Q; Li B; Liu M; Chen C; Shi Y; Xu W; Liu W; Ji S; Yu X; Xu X
World J Surg Oncol; 2024 Jan; 22(1):1. PubMed ID: 38169384
[TBL] [Abstract][Full Text] [Related]
15. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
[TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics and surgical outcomes of resectable acinar cell carcinoma of the pancreas-propensity score matching analysis with pancreatic ductal adenocarcinoma.
Chen H; Xu Z; Shen Z; Weng Y; Wang W; Ying X; Wang X; Deng X; Shen B
Eur J Surg Oncol; 2022 May; 48(5):1062-1067. PubMed ID: 34887166
[TBL] [Abstract][Full Text] [Related]
17. Conventional partial pancreatoduodenectomy versus an extended pancreatoduodenectomy (triangle operation) for pancreatic head cancers-study protocol for the randomised controlled TRIANGLE trial.
Heger P; Hackert T; Diener MK; Feißt M; Klose C; Dörr-Harim C; Möhlenbrock F; Büchler MW; Mihaljevic AL
Trials; 2023 May; 24(1):363. PubMed ID: 37254179
[TBL] [Abstract][Full Text] [Related]
18. Validation of the Anatomical and Biological Definitions of Borderline Resectable Pancreatic Cancer According to the 2017 International Consensus for Survival and Recurrence in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Upfront Surgery.
Lee B; Yoon YS; Kang M; Park Y; Lee E; Jo Y; Lee JS; Lee HW; Cho JY; Han HS
Ann Surg Oncol; 2023 Jun; 30(6):3444-3454. PubMed ID: 36695994
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma.
Maggino L; Malleo G; Marchegiani G; Viviani E; Nessi C; Ciprani D; Esposito A; Landoni L; Casetti L; Tuveri M; Paiella S; Casciani F; Sereni E; Binco A; Bonamini D; Secchettin E; Auriemma A; Merz V; Simionato F; Zecchetto C; D'Onofrio M; Melisi D; Bassi C; Salvia R
JAMA Surg; 2019 Oct; 154(10):932-942. PubMed ID: 31339530
[TBL] [Abstract][Full Text] [Related]
20. Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes.
Harrison JM; Wo JY; Ferrone CR; Horick NK; Keane FK; Qadan M; Lillemoe KD; Hong TS; Clark JW; Blaszkowsky LS; Allen JN; Castillo CF
Ann Surg Oncol; 2020 May; 27(5):1400-1406. PubMed ID: 31758284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
